Product Code: TMRGL56133
The report provides revenue of the global particle therapy market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global particle therapy market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the particle therapy market.
The report delves into the competitive landscape of the global particle therapy market. Key players operating in the global particle therapy market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global particle therapy market profiled in this report.
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Particle Therapy Market
4. Market Overview
- 4.1. Introduction
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Particle Therapy Market Analysis and Forecast, 2017-2031
- 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
- 5.1. Technological Advancements
- 5.2. Reimbursement Scenario
- 5.3. Particle Therapy Facilities In Clinical Operation, 2021
- 5.4. Average Prices, by Region, 2021
- 5.5. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
6. Global Particle Therapy Market Analysis and Forecast, By Therapy
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Therapy, 2017-2031
- 6.3.1. Proton Therapy
- 6.3.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 6.4. Market Attractiveness Analysis, By Therapy
7. Global Particle Therapy Market Analysis and Forecast, By Application
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Application, 2017-2031
- 7.3.1. Pediatric Cancer
- 7.3.2. Lung Cancer
- 7.3.3. Bladder Cancer
- 7.3.4. Brain & Spinal Cord Tumors (BSCT)
- 7.3.5. Breast Cancer
- 7.3.6. Gastrointestinal (GI) Cancers
- 7.3.7. Hepatocellular Carcinoma (HCC)
- 7.3.8. Head & Neck Cancers (HNC)
- 7.3.9. Others
- 7.4. Market Attractiveness Analysis, By Application
8. Global Particle Therapy Market Analysis and Forecast, By Service
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by Service, 2017-2031
- 8.3.1. Cyclotrons
- 8.3.2. Synchrotrons
- 8.3.3. Synchrocyclotrons
- 8.4. Market Attractiveness Analysis, By Service
9. Global Particle Therapy Market Analysis and Forecast, By End-user
- 9.1. Introduction & Definition
- 9.2. Key Findings / Developments
- 9.3. Market Value Forecast, by End-user, 2017-2031
- 9.3.1. Hospitals
- 9.3.2. Academic & Research Centers
- 9.4. Market Attractiveness Analysis, By End-user
10. Global Particle Therapy Market Analysis and Forecast, By Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Rest of the World
- 10.3. Market Attractiveness Analysis, By Region
11. North America Particle Therapy Market Analysis and Forecast
- 11.1. Introduction
- 11.2. Market Value Forecast, by Therapy, 2017-2031
- 11.2.1. Proton Therapy
- 11.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 11.3. Market Value Forecast, by Application, 2017-2031
- 11.3.1. Pediatric Cancer
- 11.3.2. Lung Cancer
- 11.3.3. Bladder Cancer
- 11.3.4. Brain & Spinal Cord Tumors (BSCT)
- 11.3.5. Breast Cancer
- 11.3.6. Gastrointestinal (GI) Cancers
- 11.3.7. Hepatocellular Carcinoma (HCC)
- 11.3.8. Head & Neck Cancers (HNC)
- 11.3.9. Others
- 11.4. Market Value Forecast, by Service, 2017-2031
- 11.4.1. Cyclotrons
- 11.4.2. Synchrotrons
- 11.4.3. Synchrocyclotrons
- 11.5. Market Value Forecast, by End-user, 2017-2031
- 11.5.1. Hospitals
- 11.5.2. Academic & Research Centers
- 11.6. Market Value Forecast, by Country, 2017-2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Therapy
- 11.7.2. By Application
- 11.7.3. By Service
- 11.7.4. By End-user
- 11.7.5. By Country
12. Europe Particle Therapy Market Analysis and Forecast
- 12.1. Introduction
- 12.2. Market Value Forecast, by Therapy, 2017-2031
- 12.2.1. Proton Therapy
- 12.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 12.3. Market Value Forecast, by Application, 2017-2031
- 12.3.1. Pediatric Cancer
- 12.3.2. Lung Cancer
- 12.3.3. Bladder Cancer
- 12.3.4. Brain & Spinal Cord Tumors (BSCT)
- 12.3.5. Breast Cancer
- 12.3.6. Gastrointestinal (GI) Cancers
- 12.3.7. Hepatocellular Carcinoma (HCC)
- 12.3.8. Head & Neck Cancers (HNC)
- 12.3.9. Others
- 12.4. Market Value Forecast, by Service, 2017-2031
- 12.4.1. Cyclotrons
- 12.4.2. Synchrotrons
- 12.4.3. Synchrocyclotrons
- 12.5. Market Value Forecast, by End-user, 2017-2031
- 12.5.1. Hospitals
- 12.5.2. Academic & Research Centers
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Spain
- 12.6.5. Italy
- 12.6.6. Rest of Europe
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Therapy
- 12.7.2. By Application
- 12.7.3. By Service
- 12.7.4. By End-user
- 12.7.5. By Country/Sub-region
13. Asia Pacific Particle Therapy Market Analysis and Forecast
- 13.1. Introduction
- 13.2. Market Value Forecast, by Therapy, 2017-2031
- 13.2.1. Proton Therapy
- 13.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 13.3. Market Value Forecast, by Application, 2017-2031
- 13.3.1. Pediatric Cancer
- 13.3.2. Lung Cancer
- 13.3.3. Bladder Cancer
- 13.3.4. Brain & Spinal Cord Tumors (BSCT)
- 13.3.5. Breast Cancer
- 13.3.6. Gastrointestinal (GI) Cancers
- 13.3.7. Hepatocellular Carcinoma (HCC)
- 13.3.8. Head & Neck Cancers (HNC)
- 13.3.9. Others
- 13.4. Market Value Forecast, by Service, 2017-2031
- 13.4.1. Cyclotrons
- 13.4.2. Synchrotrons
- 13.4.3. Synchrocyclotrons
- 13.5. Market Value Forecast, by End-user, 2017-2031
- 13.5.1. Hospitals
- 13.5.2. Academic & Research Centers
- 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Therapy
- 13.7.2. By Application
- 13.7.3. By Service
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region
14. Rest of the World Particle Therapy Market Analysis and Forecast
- 14.1. Introduction
- 14.2. Market Value Forecast, by Therapy, 2017-2031
- 14.2.1. Proton Therapy
- 14.2.2. Heavy Ion Therapy (carbon therapy, He, pion)
- 14.3. Market Value Forecast, by Application, 2017-2031
- 14.3.1. Pediatric Cancer
- 14.3.2. Lung Cancer
- 14.3.3. Bladder Cancer
- 14.3.4. Brain & Spinal Cord Tumors (BSCT)
- 14.3.5. Breast Cancer
- 14.3.6. Gastrointestinal (GI) Cancers
- 14.3.7. Hepatocellular Carcinoma (HCC)
- 14.3.8. Head & Neck Cancers (HNC)
- 14.3.9. Others
- 14.4. Market Value Forecast, by Service, 2017-2031
- 14.4.1. Cyclotrons
- 14.4.2. Synchrotrons
- 14.4.3. Synchrocyclotrons
- 14.5. Market Value Forecast, by End-user, 2017-2031
- 14.5.1. Hospitals
- 14.5.2. Academic & Research Centers
- 14.6. Market Attractiveness Analysis
- 14.6.1. By Therapy
- 14.6.2. By Application
- 14.6.3. By Service
- 14.6.4. By End-user
15. Competition Landscape
- 15.1. Market Player - Competition Matrix (by tier and size of companies)
- 15.2. Market Share Analysis, by Company, 2020
- 15.3. Company Profiles
- 15.3.1. Advanced Oncotherapy plc
- 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.1.2. Product Portfolio
- 15.3.1.3. SWOT Analysis
- 15.3.1.4. Strategic Overview
- 15.3.2. Danfysik A/S
- 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.2.2. Product Portfolio
- 15.3.2.3. SWOT Analysis
- 15.3.2.4. Strategic Overview
- 15.3.3. Hitachi, Ltd.
- 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.3.2. Product Portfolio
- 15.3.3.3. SWOT Analysis
- 15.3.3.4. Strategic Overview
- 15.3.4. IBA Worldwide
- 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.4.2. Product Portfolio
- 15.3.4.3. SWOT Analysis
- 15.3.4.4. Strategic Overview
- 15.3.5. Mevion Medical Systems, Inc.
- 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.5.2. Product Portfolio
- 15.3.5.3. SWOT Analysis
- 15.3.5.4. Strategic Overview
- 15.3.6. Optivus Proton Therapy, Inc.
- 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.6.2. Product Portfolio
- 15.3.6.3. SWOT Analysis
- 15.3.6.4. Strategic Overview
- 15.3.7. Protom International, Inc.
- 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.7.2. Product Portfolio
- 15.3.7.3. SWOT Analysis
- 15.3.7.4. Strategic Overview
- 15.3.8. Provision Healthcare
- 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.8.2. Product Portfolio
- 15.3.8.3. SWOT Analysis
- 15.3.8.4. Strategic Overview
- 15.3.9. Sumitomo Heavy Industries, Ltd.
- 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.9.2. Product Portfolio
- 15.3.9.3. SWOT Analysis
- 15.3.9.4. Strategic Overview
- 15.3.10. Varian Medical Systems, Inc.
- 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 15.3.10.2. Product Portfolio
- 15.3.10.3. SWOT Analysis
- 15.3.10.4. Strategic Overview